Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antroquinonol · 1 trial · 1 indication
Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.
| Arm | Type | Description |
|---|---|---|
| Antroquinonol (Hocena) | EXPERIMENTAL | patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first. |
| Name | Type | Description |
|---|---|---|
| Antroquinonol | DRUG | patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first. |
Inclusion Criteria: * Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion). * Radiologically confirmed disease progression following two previous lines of anti-cancer therapy, one of which should be a platinum based regimen, OR the patient has refused t...
Antroquinonol is an investigational small molecule being studied for the treatment of Stage IV Non-small Cell Lung Cancer (NSCLC). It is currently in clinical development and has not been approved by regulatory authorities. A Phase 2 trial has been completed to evaluate its efficacy, safety, and pharmacokinetics in patients with this condition.
Antroquinonol is being developed by Icon Plc, a company listed on the NASDAQ under the ticker symbol ICLR. The company is conducting clinical research on this investigational drug for the treatment of Stage IV Non-small Cell Lung Cancer.
Antroquinonol is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational. It has not received FDA approval and is still undergoing clinical evaluation for its safety and efficacy in treating Stage IV Non-small Cell Lung Cancer.
Antroquinonol has one completed clinical trial registered under NCT02047344, titled 'Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC.' This Phase 2 study enrolled 31 participants with Stage IV Non-small Cell Lung Cancer and was conducted in the United States and Taiwan.
Antroquinonol is the primary name for this investigational drug. No alternative names have been established in the available clinical trial information. It is being studied under the identifier NCT02047344 for its potential use in treating Stage IV Non-small Cell Lung Cancer.